These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2887641)

  • 21. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
    Choy H; Yee L; Cole BF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of taxol in patients with metastatic renal cell carcinoma.
    Einzig AI; Gorowski E; Sasloff J; Wiernik PH
    Cancer Invest; 1991; 9(2):133-6. PubMed ID: 1677827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
    Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
    Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequences of taxol and cisplatin: a phase I and pharmacologic study.
    Rowinsky EK; Gilbert MR; McGuire WP; Noe DA; Grochow LB; Forastiere AA; Ettinger DS; Lubejko BG; Clark B; Sartorius SE
    J Clin Oncol; 1991 Sep; 9(9):1692-703. PubMed ID: 1678780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
    Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
    J Clin Oncol; 1993 May; 11(5):950-8. PubMed ID: 8098059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
    Kobierski J; Majdak E; Mielcarek P; Emerich J
    Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of taxol using a 5-day intermittent schedule.
    Legha SS; Tenney DM; Krakoff IR
    J Clin Oncol; 1986 May; 4(5):762-6. PubMed ID: 2871137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):3-8. PubMed ID: 7939760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
    Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
    Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
    Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.
    Bissett D; Setanoians A; Cassidy J; Graham MA; Chadwick GA; Wilson P; Auzannet V; Le Bail N; Kaye SB; Kerr DJ
    Cancer Res; 1993 Feb; 53(3):523-7. PubMed ID: 8093854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
    Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.